Related Experiment Video

Updated: May 23, 2026

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

[Impact of CACNA1C polymorphisms on antihypertensive efficacy of calcium channel blocker]

Qian Sun1, Qing-xian Li, Xi-fa Song

  • 1Department of Clinical Laboratory, Wenzhou Medical College, Wenzhou, China.

Zhonghua Xin Xue Guan Bing Za Zhi
|April 12, 2012
PubMed

Insights

Genetic variations in CACNA1C influence calcium channel blocker efficacy for essential hypertension. Patients with wild genotypes of rs2299661 and rs216008 showed better blood pressure reduction with CCB monotherapy.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Essential hypertension (EH) is a prevalent cardiovascular condition.
  • Calcium channel blockers (CCBs) are widely used for hypertension management.
  • Genetic factors may influence individual responses to CCB therapy.

Purpose of the Study:

  • To investigate the association between CACNA1C gene polymorphisms and the effectiveness of CCB (Nifedipine) in Han Chinese patients with essential hypertension.
  • To identify genetic markers that predict CCB response in this population.

Main Methods:

  • Genotyping of five CACNA1C single nucleotide polymorphisms (SNPs): rs216008, rs1051375, rs2299661, rs10848683, and rs215976 using Multiplex PCR and MLDI-TOF MS.
  • Comparison of blood pressure reduction after CCB monotherapy (Nifedipine 20 mg/d) among patients with different genotypes.
  • Enrollment of 103 EH patients from Wenzhou.

Main Results:

  • CCB treatment significantly reduced blood pressure in all patients (P < 0.05).
  • Greater reduction in diastolic blood pressure was observed in patients with the rs2299661 C/C (wild) genotype compared to mutational genotypes (P < 0.05).
  • Greater reduction in systolic blood pressure was observed in patients with the rs216008 C/C (wild) genotype compared to the C/T (mutational) genotype (P < 0.05).
  • No significant differences in blood pressure reduction were found for genotypes rs1051375, rs10848683, and rs215976.

Conclusions:

  • Wild genotypes of rs2299661 and rs216008 in the CACNA1C gene are associated with a better response to CCB monotherapy in essential hypertension.
  • These findings suggest potential for genotype-guided CCB selection in EH patients.
  • CACNA1C polymorphisms may serve as predictive biomarkers for CCB efficacy.
Abstract

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...